



2017 turnover Upcoming CE marking Ongoing R&D projects

In K€	2017	2016	Evolution in %
Turnover	1,612	1,525	+ 6 %

I.Ceram, specialized in innovative orthopedic implants and ceramic implants, announces for 2017 a turnover of 1,612 K€ from its historical products, with an increase of +6% in comparison to 2016. During 2017, the company followed its research on releasing implants and made possible the first implantation of an antibiotic loaded alumina ceramic to replace a portion of the distal part of a femur presenting chronic osteomyelitis.

This innovation validates the company's capacity to design pieces with different shapes and volumes and confirms the potential therapeutic property of its loaded implants. The porous structure of Ceramil® implants allows the local release of antibiotic with an efficient concentration several days after surgery.

The high added-value of these implants consolidates the I.Ceram's strategy to focus on the reinforcement and deployment of its porous alumina ceramics range. Ceramil® implants sales increased by 10% during 2017. As real growth levers, these implants should, in the future, be a significant part of I.Ceram's turnover.

2018: CE marking and sternum commercialization

The company will have its audit for CE marking before the end of first quarter 2018. The delay is a consequence of European regulation applied to notified body, which affected the time for file approval. I.Ceram's filings were sent in June 2016. However, I.Ceram's commercial team is already in the starting-block to sell unloaded sternums as soon as the CE mark will be obtained. This distribution will rely on its historical French commercial team and on international ones (Italy, UK, Belgium, Spain and Czech Republic). The international commercial teams are being reinforced thanks to an investment in a company based in South Africa.

Thanks to the success of the first 10 ceramic sternum prosthesis implantations and after CE mark approval, I.Ceram is confident about the development of this product which should become a significant part of 2018 activity.

New R&D projects

R&D teams are actively involved in new R&D projects, bringing innovation to help patients with new implantations but also *in vitro* studies in order to modify the surface characteristics of the implants. Thus R&D goals have been clearly defined for 2018:

- Designing a long-acting protection of implants against bacteria
- Designing 2 types of new porous alumina implants
- Implantation of a piece in another type of surgical indication

During 2018, I.Ceram will issue strategic deployments to confirm its leading position in the treatment of bone infections.

Next press release:

Annual results for 2017: March 22th, 2018

All information is available on www.iceram.fr

About I.CERAM:

Created in 2005 in Limoges, France, I.CERAM designs, manufactures and commercializes orthopedic implants and ceramic implants offering a unique biocompatibility (11 international patents). The wealth of knowledge and expertise from over 30 years of its managers has enabled I.CERAM to accelerate its bioceramic development. I.CERAM is labeled as an "innovative company", ISO 14385:2012 certified and CE certified. With 46 employees and a production tool at the forefront of technology, I.CERAM shows a very high potential to continuously develop. On December 2014, the company was listed on the Euronext Growth exchange (Euronext Paris). ISIN: FR0011511971 – ALICR

Contacts :


IMPLANTS DE HAUTE TECHNOLOGIE
Investor Relations
Christophe Durivault
Tél : +33 (0)5 55 69 12 12
finances@iceram.fr



Financial Communications
Solène Kennis
Tel : +33 (0)1 75 77 54 68
skennis@aelium.fr

ARROWHEAD
BUSINESS AND INVESTMENT DECISIONS

Investor Relations – USA
Thomas Renaud or Daniel Renaud
Tel: +1 212 619-6889 ext. 7010
i.ceram@arrowheadbid.com